Showing results (441-450 of 537) with videos related to
Sort By:
Pageof 54
Headache|February 20, 2020
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and IIDavid W Dodick, Richard B Lipton, Jessica Ailani, et al.Cephalalgia : an International Journal of Headache|November 26, 2020
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implicationsPeter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, et al.Nature Medicine|May 12, 2025
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trialPeter J Goadsby, Jessica Ailani, David W Dodick, et al.Cephalalgia : an International Journal of Headache|November 2, 2020
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraineCaroline M Kopruszinski, Peter Thornton, Joanne Arnold, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 29, 2014
Association of ischemic stroke, hormone therapy, and right to left shunt in postmenopausal womenNancy C Greep, David S Liebeskind, Rubine Gevorgyan, et al.Neurology|May 3, 2015
Milestone-compatible neurology resident assessments: A role for observable practice activitiesLyell K Jones, Elliot L Dimberg, Christopher J Boes, et al.Cephalalgia : an International Journal of Headache|March 27, 2023
Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employeesFumihiko Sakai, Hisaka Igarashi, Masako Yokoyama, et al.Headache|September 6, 2016
Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 StudyStephen D Silberstein, Laszlo L Mechtler, David B Kudrow, et al.Cephalalgia : an International Journal of Headache|May 13, 2022
Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headacheEdita Navratilova, Janice Oyarzo, Trent Anderson, et al.Plos One|July 12, 2018
Sub-classifying patients with mild traumatic brain injury: A clustering approach based on baseline clinical characteristics and 90-day and 180-day outcomesBing Si, Gina Dumkrieger, Teresa Wu, et al.Pageof 54